Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision
Respirology · 2024-02 · 29 (2) · 105-135
DOI: 10.1111/resp.14656 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respirology, online erschienen am 11.01.2024. Verfasst von John A Mackintosh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 291 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHMRC, The Thoracic Society of Australia and New Zealand and Lung Foundation Australia, National Health and Medical Research Council.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia.
- Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.
- Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
- University of Sydney, Sydney, New South Wales, Australia.
- Department of Physiotherapy, The Alfred Hospital, Melbourne, Victoria, Australia.
ORCID-Profile: John A Mackintosh, Gregory Keir, Anne E Holland, Christopher Grainge, Daniel C Chambers, Ian Glaspole, Margaret Wilsher, Nicole S L Goh, Paul N Reynolds, Yuben Moodley, Tamera J Corte
Förderung
- NHMRC
- The Thoracic Society of Australia and New Zealand and Lung Foundation Australia
- National Health and Medical Research Council
Zitieren
APA
Mackintosh, J. A., Keir, G., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., Wilsher, M., Goh, N. S. L., Reynolds, P. N., Chapman, S., Mutsaers, S. E., de Boer, S., Webster, S., Moodley, Y., & Corte, T. J. (2024). Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology, 29(2), 105-135. https://doi.org/10.1111/resp.14656
Vancouver
Mackintosh JA, Keir G, Troy LK, Holland AE, Grainge C, Chambers DC, et al. Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology. 2024;29(2):105-135. doi:10.1111/resp.14656
BibTeX
@article{Mackintosh2024,
author = {Mackintosh, John A and Keir, Gregory and Troy, Lauren K and Holland, Anne E and Grainge, Christopher and Chambers, Daniel C and Sandford, Debra and Jo, Helen E and Glaspole, Ian and Wilsher, Margaret and Goh, Nicole S L and Reynolds, Paul N and Chapman, Sally and Mutsaers, Steven E and de Boer, Sally and Webster, Susanne and Moodley, Yuben and Corte, Tamera J},
title = {Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision},
journal = {Respirology},
year = {2024},
volume = {29},
number = {2},
pages = {105--135},
doi = {10.1111/resp.14656}
}
EUVIMED